当前位置: 首页 >> 检索结果
361. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
作者: Andrea Rubbert-Roth.;Paul P Tak.;Cristiano Zerbini.;Jean-Luc Tremblay.;Luis Carreño.;Gillian Armstrong.;Neil Collinson.;Tim M Shaw.; .
来源: Rheumatology (Oxford). 2010年49卷9期1683-93页
To evaluate the efficacy and safety of three dosing and repeat treatment regimens of rituximab (RTX) plus MTX in patients with active RA.
362. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis.
作者: An D Billiau.;Michèle Loop.;Phu-Quoc Le.;Françoise Berthet.;Pierre Philippet.;Ahmad Kasran.;Carine H Wouters.
来源: Rheumatology (Oxford). 2010年49卷8期1550-8页
Chronic inflammation in juvenile idiopathic arthritis interferes with linear growth and bone mass acquisition. We prospectively evaluated and compared linear growth and evolution of bone mass acquisition and body composition in MTX-resistant polyarticular-course JIA (polyJIA) patients started on etanercept and in recently diagnosed polyJIA patients started on MTX monotherapy.
363. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis.
作者: Hala Y Sadik.;Tonia L Moore.;Andy Vail.;Andrea Murray.;Marina Anderson.;Andrew Blann.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2010年49卷5期990-6页
The aim of this study was to test the hypothesis that statin therapy confers benefit on the microvasculature, including improving endothelial function, in patients with SSc.
364. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial.
作者: Puja P Khanna.;Daniel E Furst.;Philip J Clements.;Paul Maranian.;Lilavati Indulkar.;Dinesh Khanna.; .
来源: Rheumatology (Oxford). 2010年49卷5期955-9页
To characterize the baseline tendon friction rubs (TFRs) in early dcSSc and to evaluate the association of change in TFR over 6 and 12 months with changes in modified Rodnan skin score (MRSS) and HAQ-Disability Index (HAQ-DI) over 12 and 24 months, respectively.
365. How to improve DAS28 use in daily clinical practice?--a pilot study of a nurse-led intervention.
作者: Laura T C van Hulst.;Marjonne C W Creemers.;Jaap Fransen.;Linda C Li.;Richard Grol.;Marlies E J L Hulscher.;Piet L C M van Riel.
来源: Rheumatology (Oxford). 2010年49卷4期741-8页
To determine whether DAS28 measurements by a specialized nurse, before the rheumatologist visit, in combination with the advice to rheumatologists to reach a DAS28 < or = 3.2, had beneficial effects on disease activity and medication prescription in patients with RA and to explore possible predictors for variation in medication changes and reasons for non-adherence to the advice to reach a DAS28 < or = 3.2.
366. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
作者: Bridget Griffiths.;Paul Emery.;Vicky Ryan.;David Isenberg.;Mohammed Akil.;Robert Thompson.;Peter Maddison.;Ian D Griffiths.;Alice Lorenzi.;Sarah Miles.;Deva Situnayake.;Lee Suan Teh.;Mike Plant.;Christina Hallengren.;Ola Nived.;Gunnar Sturfelt.;Kuntal Chakravarty.;Tim Tait.;Caroline Gordon.
来源: Rheumatology (Oxford). 2010年49卷4期723-32页
To determine whether low-dose ciclosporin was a more effective corticosteroid-sparing agent than AZA in patients with SLE.
367. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
作者: Van Anh Nguyen.;Klaus Eisendle.;Ingrid Gruber.;Beate Hugl.;Daniela Reider.;Norbert Reider.
来源: Rheumatology (Oxford). 2010年49卷3期583-7页
To investigate the efficacy of the endothelin receptor antagonist, bosentan, in patients with RP secondary to SSc without pre-existing digital ulcers.
368. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.
To evaluate the clinical relevance of CRP in AS and investigate the treatment effect of NSAIDs/coxibs on CRP.
369. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.
作者: Vedat Hamuryudan.;Gulen Hatemi.;Koray Tascilar.;Necdet Sut.;Yilmaz Ozyazgan.;Emire Seyahi.;Cem Mat.;Sebahattin Yurdakul.;Hasan Yazici.
来源: Rheumatology (Oxford). 2010年49卷1期173-7页
To assess the influence of being free of major organ involvement during the early years of the disease on the prognosis of men with Behçet's syndrome (BS).
370. Maintenance of physical activity after Internet-based physical activity interventions in patients with rheumatoid arthritis.
作者: Emalie J Hurkmans.;Marleen H van den Berg.;Karel H Ronday.;Andreas J Peeters.;Saskia le Cessie.;Theodora P M Vliet Vlieland.
来源: Rheumatology (Oxford). 2010年49卷1期167-72页
To investigate the maintenance of physical activity 12 months after two 1-year Internet-based physical activity interventions in patients with RA.
371. A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility.
作者: Sue Kemp.;Ian Roberts.;Carrol Gamble.;Stuart Wilkinson.;Joyce E Davidson.;Eileen M Baildam.;Andrew Gavin Cleary.;Liza J McCann.;Michael W Beresford.
来源: Rheumatology (Oxford). 2010年49卷2期315-25页
Joint hypermobility, common in childhood, can be associated with severe pain and significant morbidity. Physiotherapy, the mainstay of treatment, lacks a robust evidence base. This study is aimed at determining the best physiotherapy intervention in managing childhood hypermobility.
372. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
作者: David Isenberg.;Gerald B Appel.;Gabriel Contreras.;Mary A Dooley.;Ellen M Ginzler.;David Jayne.;Jorge Sánchez-Guerrero.;David Wofsy.;Xueqing Yu.;Neil Solomons.
来源: Rheumatology (Oxford). 2010年49卷1期128-40页
To compare the efficacy and safety of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC) as induction treatment for lupus nephritis (LN), by race, ethnicity and geographical region.
373. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.
作者: Dinesh Khanna.;Chi-Hong Tseng.;Daniel E Furst.;Philip J Clements.;Robert Elashoff.;Michael Roth.;David Elashoff.;Donald P Tashkin.; .
来源: Rheumatology (Oxford). 2009年48卷12期1537-40页
Scleroderma Lung Study (SLS) showed that cyclophosphamide (CYC) was better than placebo (PLA) in preventing progression of forced vital capacity percentage (FVC%) predicted and dyspnoea at 12 months. Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS.
374. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
作者: Martin Soubrier.;Xavier Puéchal.;Jean Sibilia.;Xavier Mariette.;Olivier Meyer.;Bernarde Combe.;René Marc Flipo.;Denis Mulleman.;Francis Berenbaum.;Charles Zarnitsky.;Thierry Schaeverbeke.;Patrice Fardellone.;Maxime Dougados.
来源: Rheumatology (Oxford). 2009年48卷11期1429-34页
In early and active RA despite MTX, continuous treatment with TNF blockers in combination with MTX is recommended. To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status.
375. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome.
作者: Hasan Kiliç.;Hasan E Zeytin.;Cengiz Korkmaz.;Cem Mat.;Ahmet Gül.;Fulya Coşan.;Ayhan Dinç.;Ismail Simşek.;Necdet Süt.;Hasan Yazici.
来源: Rheumatology (Oxford). 2009年48卷11期1388-91页
There had been evidence that low-dose local IFN could be beneficial in the management of recurrent oral ulcers (OUs). We investigated the efficacy and collected initial data on the safety of low-dose natural human IFN-alpha administered by the oral mucosal route in Behçet's syndrome (BS) in a placebo controlled, double blind study.
376. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study.
作者: Aslam Anis.;Wei Zhang.;Paul Emery.;Huiying Sun.;Amitabh Singh.;Bruce Freundlich.;Reiko Sato.
来源: Rheumatology (Oxford). 2009年48卷10期1283-9页
To compare the impact of the combination of etanercept (ETN) and MTX with MTX alone on work productivity among MTX-naïve patients with active early RA over a 12-month period.
377. Improvements of muscle strength predicted benefits in HRQOL and postural balance in women with fibromyalgia: an 8-month randomized controlled trial.
作者: Pablo Tomas-Carus.;Narcis Gusi.;Arja Häkkinen.;Keijo Häkkinen.;Armando Raimundo.;Alfredo Ortega-Alonso.
来源: Rheumatology (Oxford). 2009年48卷9期1147-51页
To evaluate whether changes in muscle strength due to 32 weeks of supervised aquatic training predicted improvements on health-related quality of life (HRQOL).
378. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
作者: Marian Kaldas.;Puja P Khanna.;Daniel E Furst.;Philip J Clements.;Weng Kee Wong.;James R Seibold.;Arnold E Postlethwaite.;Dinesh Khanna.; .
来源: Rheumatology (Oxford). 2009年48卷9期1143-6页
The modified Rodnan skin score (MRSS) is a standard outcome measure for skin disease in SSc and calculated by summation of skin thickness in 17 different body sites (total score = 51). Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS.
379. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
作者: Nathan Vastesaeger.;Stephen Xu.;Daniel Aletaha.;E William St Clair.;Josef S Smolen.
来源: Rheumatology (Oxford). 2009年48卷9期1114-21页
Identifying patients with RA at high risk of rapid radiographic progression (RRP) is critical for making appropriate treatment decisions. We developed an exploratory prediction model for the risk of RRP using an RA study population undergoing either conservative or aggressive disease management.
380. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
作者: Edmund K Li.;Lai-Shan Tam.;Tracy Y Zhu.;Martin Li.;Catherine L Kwok.;Tena K Li.;Ying Ying Leung.;Kong Chiu Wong.;Cheuk Chun Szeto.
来源: Rheumatology (Oxford). 2009年48卷8期892-8页
To assess if combination rituximab and cyclophosphamide is more effective than rituximab monotherapy as an induction therapy for proliferative lupus nephritis.
|